RVNC vs. MRSN, STTK, GBIO, NGM, HRTX, ABCL, ELVN, COLL, PRTA, and ARQT
Should you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include Mersana Therapeutics (MRSN), Shattuck Labs (STTK), Generation Bio (GBIO), NGM Biopharmaceuticals (NGM), Heron Therapeutics (HRTX), AbCellera Biologics (ABCL), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Prothena (PRTA), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "medical" sector.
Mersana Therapeutics (NASDAQ:MRSN) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.
Revance Therapeutics has a net margin of -134.10% compared to Revance Therapeutics' net margin of -352.01%. Mersana Therapeutics' return on equity of 0.00% beat Revance Therapeutics' return on equity.
Revance Therapeutics received 152 more outperform votes than Mersana Therapeutics when rated by MarketBeat users. However, 65.78% of users gave Mersana Therapeutics an outperform vote while only 63.88% of users gave Revance Therapeutics an outperform vote.
Mersana Therapeutics has higher earnings, but lower revenue than Revance Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Mersana Therapeutics and Mersana Therapeutics both had 4 articles in the media. Revance Therapeutics' average media sentiment score of 1.26 beat Mersana Therapeutics' score of 0.87 indicating that Mersana Therapeutics is being referred to more favorably in the media.
Mersana Therapeutics currently has a consensus target price of $6.29, suggesting a potential upside of 161.90%. Revance Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 330.71%. Given Mersana Therapeutics' higher possible upside, analysts plainly believe Revance Therapeutics is more favorable than Mersana Therapeutics.
93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are held by institutional investors. 11.8% of Mersana Therapeutics shares are held by insiders. Comparatively, 3.5% of Revance Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Mersana Therapeutics has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
Summary
Mersana Therapeutics beats Revance Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Revance Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revance Therapeutics Competitors List
Related Companies and Tools
